Global Relay Intelligence & Practice
All the latest news, insights, and publications from Global Relay.
Latest stories
The US Food and Drug Administration has issued a proposed rule to classify medical device accessories separately, aiming to clarify regulatory oversight.
Balancing efficiency benefits and risk potential requires formal oversight and purpose-built governance frameworks, our experts agree.
Autonomous AI-based trading strategies could complicate questions of firms’ responsibility for model behavior.
The US Food and Drug Administration has granted clearance to Vitestro’s Aletta device, easing phlebotomist shortages.
Highlights
Spotlight
Related articles
Industries Feed
Podcasts
Compliance
A discussion on the US Government’s comment submission and whether, as Andrew Puzder, the US Ambassador to the EU suggests, “Now it's time for the EU to deliver.”
The Australian Securities and Investments Commission’s latest actions and news, August 6-20.
In this final article in our NFM series, we consider some of the practical challenges firms may face when investigating allegations of non-financial misconduct.
Epic’s new API lets clinicians instantly see insurer authorization requirements, launching ahead of a 2027 federal interoperability deadline.
Regulation
Companies that secretly vary prices based on how much they think individual customers will pay could be violating the FTC Act.
Costco to begin selling Medicare plans as retailer expands health push
Warehouse giant partners with Scan Health Plan to offer Medicare Advantage and supplemental plans, extending its growing footprint in low‑cost healthcare services.
White House health adviser Heidi Overton is set to be nominated to lead the FDA, succeeding Marty Makary amid agency turnover and ongoing policy disputes.
Our regular roundup of the latest news and developments from the FCA.
Technology
Finansinspektionen (FI) warns of evolving investment fraud threats with fraudsters harnessing AI to enhance their credibility.
This article explains the UK's policy statement PS26/10 for qualifying stablecoins and compares its requirements to the EU's.
Tony McClements argues that treating graduates as expendable overheads in comparison to AI systems is "ultimately managerial vandalism."
Discussion paper outlines risks, evaluation needs, and oversight options as FDA develops regulatory framework for GenAI‑enabled medical devices.
Get full access, free for a month
Stay ahead with the compliance and regulatory insight you need. Start your 28-day free trial to access all content on GRIP – no payment details required.
What’s included:
- Every new article, plus our 5,000+ archive
- Daily regulatory insight and guidance
- Exclusive interviews and in-depth analysis
- Coverage of industry-leading events and conferences
- All podcasts and videos, featuring industry experts
- The full set of Rules Navigator tools
- An ad-free experience
Mitigating NFM risk in the spotlight